**Breaking News** Little Known Biotech Company Does $41 Million In Q1!

[Investment House] Below please find a special message from one of our sponsors, BioStem Technologies, Inc. From time to time we find special opportunities we believe you as a valued customer may want to see. Please note that the following message reflects the opinions and representations of our sponsor alone, and not necessarily the opinion or editorial positions of Investment House, Eagle Financial Publications or Salem Media Group. --------------------------------------------------------------- [Picture1]( [Revenues continue to explode for this growing MedTech firm that just got another price increase from Zack’s Small Cap Research to $23.25!]( The growing MedTech arena is home to some notable players but one company is uniquely standing out as its revenues explode, purchase orders accelerate, and a price target from Zack’s Small Cap Research continues to move north. BioStem Technologies, Inc. (BSEM) is changing the skin graft market by using the natural properties of perinatal tissue. Growth is rocketing as management makes smart and aggressive moves. Following 2023, a year of tremendous growth, BSEM recently released its Q1 financial results of $ 41 million that revealed the company’s first positive net income! BSEM attributes its growth to the successful launch of the company’s Amniowrap2™, an innovative placental-derived allograft product designed to address a broad spectrum of wound applications. A significant factor contributing to this success has been the widespread acceptance and utilization of Amniowrap2™ by medical professionals, underscoring its effectiveness and growing prominence in the healthcare industry. [BSEM especially gained momentum in the second half of 2023 when the Centers awarded the company a valuable Q code for its Vendaje AC and AmnioWrap2 products for Medicare and Medicaid Services.]( Most recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories. Additionally, the company isn’t resting on its success as management recently initiated a clinical trial evaluating Vendaje in diabetic foot ulcers—a market with enormous and growing potential! BSEM additionally sees an uplisting to a major exchange sooner than later! [Learn more about why Zack’s has increased its price target on BSEM to a whopping $23.25!]( This is a paid advertisement. Investment House is receiving compensation of between $3,000-$4,000 for sending this email. --------------------------------------------------------------- The foregoing is commentary for informational purposes only. All statements and expressions are the opinions of Eagle Products, LLC, or Salem Communications. This information is not meant to be a solicitation or recommendation to buy, sell, or hold securities. We are not licensed or registered in the securities industry. The information presented herein and on the related web site has been obtained from sources believed to be reliable, but its accuracy is not assured. The security portfolios of writers for this issue may, in some instances, include securities mentioned herein and on the related web site. Estimates, assumptions and other forward-looking information are subject to the limits of forecasting. Actual future developments may differ materially due to many factors. No one associated herewith receives compensation in any manner from any of the companies that are discussed in this newsletter or on the related websites. This is a commercial email. It may contain promotion or solicitation. This email was sent to {EMAIL} because you are subscribed to the Carefully Selected Financial Offers from Third Parties List. To unsubscribe please click [here](. To stop receiving emails simply click [here](. View this email in your [web browser](. All Rights Reserved. Investment House - Eagle Products, LLC - a Salem Communications Holding Company, 122 C Street NW, Suite 515, Washington, DC 20001 [Link](